Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib Plus Abemaciclib for Myelofibrosis
NCT05714072Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2023
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abemaciclib in myelofibrosis (MF), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Proportion of patients with dose-limiting toxicity at 28 days. Started Jan 2023; status: recruiting.
02
Drugs
abemaciclib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT05714072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05714072.